RVMD (Revolution Medicines) Net Margin %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RVMD Revolution Medicines Inc RVMD
25 GF Score
Price $204.86
! 3 Warning Signs
View Full Analysis

What is Revolution Medicines Net Margin %?

Revolution Medicines RVMD -0.19% 25 Net Margin % is 0.00% as of Jun. 2026. GuruFocus rates RVMD with a GF Score™ of 25/100. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Revolution Medicines ranks worse than 105820% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Revolution Medicines's Net Income for the three months ended in Jun. 2026 was $-644.37 Mil. Revolution Medicines's Revenue for the three months ended in Jun. 2026 was $0.00 Mil. Therefore, Revolution Medicines's net margin for the quarter that ended in Jun. 2026 was 0.00%.

The historical rank and industry rank for Revolution Medicines's Net Margin % or its related term are showing as below:


RVMD's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -83.18
* Ranked among companies with meaningful Net Margin % only.

Revolution Medicines  (NAS:RVMD) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Revolution Medicines Net Margin % Related Terms

Revolution Medicines Net Margin % Historical Data

* Premium members only.

The historical data trend for Revolution Medicines's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revolution Medicines Net Margin % Chart

Revolution Medicines Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only -636.58 -702.95 -3,768.28 0.00 0.00

Revolution Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RVMD vs ALNY, ONC, RPRX: Net Margin % Comparison

For the Biotechnology subindustry, Revolution Medicines's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revolution Medicines Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revolution Medicines's Net Margin % distribution charts can be found below:

* The bar in red indicates where Revolution Medicines's Net Margin % falls into.


RVMD
25GF Score
Revolution Medicines Inc RVMD
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revolution Medicines Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Revolution Medicines's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1131.301/0
= %

Revolution Medicines's Net Margin for the quarter that ended in Jun. 2026 is calculated as

Net Margin=Net Income (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-644.371/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Revolution Medicines (RVMD) has a Net Margin % of 0.00% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Revolution Medicines and its competitors. According to the industry distribution chart, Revolution Medicines ranks #999999 out of 945 companies in the Biotechnology industry.
Is Revolution Medicines' Net Margin % too high?
Revolution Medicines' current Net Margin % is 0.00%. Based on the distribution chart, Revolution Medicines ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Revolution Medicines has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Revolution Medicines' Net Margin % compare to ALNY and ONC?
According to the Biotechnology industry distribution chart, Revolution Medicines ranks #999999 out of 945 companies for Net Margin %. This places Revolution Medicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Revolution Medicines and its competitors. Revolution Medicines's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revolution Medicines stock overvalued right now?
Revolution Medicines (RVMD) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Revolution Medicines' overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Revolution Medicines (RVMD), the current Net Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revolution Medicines Business Description

Other Exchanges 1RVMD:Italy42Z:Germany
Address 700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
25GF Score

Get the complete analysis for RVMD

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$204.86
Price